Dion Marinkovich 2025 Joint Meeting of the COSA ASM and IPOS Congress

Abstracts this author is presenting:

• Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (ABC): a Subgroup Analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients from EMBER-3 — Afternoon tea, Poster session 1 & Exhibition
• Imlunestrant with or without Abemaciclib as First- (1L) and Second-line (2L) Therapy in Advanced Breast Cancer (ABC): a Subgroup Analysis from the EMBER-3 trial — Afternoon tea, Poster session 1 & Exhibition
• Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant+abemaciclib: Results from the phase III EMBER-3 trial — Afternoon tea, Poster session 1 & Exhibition